Answers are grounded in this paper and cite their sources.
CRISPR/Cas9 gene-editing technology can directly modify the genes that plays a vital role in cancer. Currently, it has been increasingly being precisely applied in cancer treatment. In vivo safe and effective delivery is still a problem that has not been solved yet. It is to be solved in current delivery system for viral vectors. For examples, they are highly immunogenic and carry the risk of random genomic integration. Synthetic non-viral vectors have poor circulatory stability and insufficient tumor accumulation. Therefore, it is difficult to achieve a good balance between safety and delivery efficiency. Extracellular vesicles (EVs) are natural, membrane-bound carriers that have low immunogenicity, can protect the contents of cells from damage in a living organism and also function as tumour-homing agents. The main ways to load CRISPR/Cas9 into EVs, some strategies for targeted modification, and problems that still need to be solved in the future will be introduced in this paper.
No takes yet. Share an insight, caveat, or question.
Zonglin Li (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: